Arrowhead begins EAP to avail plozasiran outside of trials for patients with FCS

Arrowhead Pharmaceuticals announced that it has initiated an Expanded Access Program EAP to make investigational plozasiran available outside of a clinical trial for patients with familial chylomicronemia syndrome FCS who meet certain program eligibility criteria. Arrowhead will also present new final Phase 2 clinical data from the double-blind portion of the SHASTA-2 study of plozasiran in a late-breaking oral presentation at the upcoming American College of Cardiology 73rd Annual Scientific Session & Expo ACC.24 , being held in Atlanta on April 6-8, 2024. “Arrowhead is committed to supporting patients living with various lipid disorders and the physicians who treat them. To that end, we are pleased that Dr. Daniel Gaudet, Professor of Medicine at Universite de Montreal and President and Scientific Director of ECOGENE-21, will present final data in a late-breaking oral presentation at ACC.24 from the SHASTA-2 study of plozasiran in patients with severe hypertriglyceridemia,” said Bruce Given, M.D., interim chief medical scientist at Arrowhead. “Our Phase 3 PALISADE study of plozasiran in patients with FCS is nearing completion and we are further supporting the patient community by initiating an expanded access program for patients and physicians interested in receiving treatment with plozasiran outside of a clinical trial. In addition, Arrowhead medical affairs representatives will be hosting a company booth at ACC.24 with resources for physicians to learn more about the mechanism of cardiometabolic diseases we are studying and our pipeline of RNAi therapeutics that leverage Arrowhead’s proprietary TRiM platform.”